Clinical Trial Update: A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial investigating camrelizumab plus chemotherapy versus chemotherapy alone for metastatic triple-negative breast cancer; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Conditions: Triple Negative Breast Cancer | Phase 3 | Status: TERMINATED